Literature DB >> 8179962

Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS.

M R Hilleman1.   

Abstract

Current approaches to the prevention and control of AIDS by vaccines and by chemotherapy have failed to provide satisfactory solutions to this important medical problem and have failed, in addition, to provide definitive guidelines for future research endeavor. Vaccine research must and will continue but it is possible that a safe and effective vaccine may never be developed and it may be timely to explore, in addition, alternative means for immunological intervention in AIDS. Both immunoprophylactic and immunotherapeutic efforts might be assisted by manipulating the T helper 1 (Th1) and T helper 2 (Th2) subsets of CD4+ T helper cells, which is therefore worthy of exploration. Selective control of immune response by the two T helper subsets is by release of different cytokines that promote either cellular or humoral immunity, the latter of which may be associated with inappropriate immune responses and with immune dysfunction. Discovery of the Th1 and Th2 subsets and definition of the cytokines they release provide a new avenue toward possible development of a safe and effective vaccine and an approach, in addition, to correction of immune dysfunction by selective cytokine administration or by cytokine ablation by antagonists or antibodies. AIDS pathogenesis and immune dysfunction are complex and understanding them may be overwhelmed by an excess of possibilities. Simplification of the endeavor might benefit from comparative studies of the pathogenesis of measles, in which there also is immune deficiency but usually with spontaneous viral clearance, reversal of immune dysfunction, and total recovery. In addition, measles presents as a single disease and is caused by antigenically stable virus. Identification of the process whereby measles immunodeficiency is spontaneously reversed might be of importance in attempting to devise means for similar reversal in AIDS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8179962     DOI: 10.1089/aid.1994.10.3

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

Review 1.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

2.  Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects.

Authors:  P De Paoli; S Zanussi; C Simonelli; M T Bortolin; M D'Andrea; C Crepaldi; R Talamini; M Comar; M Giacca; U Tirelli
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 3.  Interleukin-12 in infectious diseases.

Authors:  L Romani; P Puccetti; F Bistoni
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 4.  HIV preventive vaccines. Progress to date.

Authors:  J Esparza; S Osmanov; W L Heyward
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

5.  The hemagglutinin envelope protein of canine distemper virus (CDV) confers cell tropism as illustrated by CDV and measles virus complementation analysis.

Authors:  L B Stern; M Greenberg; J M Gershoni; S Rozenblatt
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 6.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

7.  Attenuated measles virus as a vaccine vector.

Authors:  Armando Zuniga; Zili Wang; Matthias Liniger; Lars Hangartner; Michael Caballero; Jovan Pavlovic; Peter Wild; Jean Francois Viret; Reinhard Glueck; Martin A Billeter; Hussein Y Naim
Journal:  Vaccine       Date:  2007-02-02       Impact factor: 3.641

8.  A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

Authors:  Clarisse Lorin; Lucile Mollet; Frédéric Delebecque; Chantal Combredet; Bruno Hurtrel; Pierre Charneau; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.